author-photo

Wendy Crist

GlaxoSmithKline

4

Papers

1656

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

2015 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (1626)
LBA4_PRCOMBI-V: A RANDOMISED, OPEN-LABEL, PHASE III STUDY COMPARING THE COMBINATION OF DABRAFENIB (D) AND TRAMETINIB (T) WITH VEMURAFENIB (V) AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH UNRESECTABLE OR METASTATIC BRAF V600E/K MUTATION-POSITIVE CUTANEOUS MELANOMA

2014 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (6)
METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM).

2012 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (24)